Cosmos Health Inc. Common Stock (COSM)
Stock · NASDAQ · Health Care
$0.3312as of 10/16/2026
Price chart
Active signals
High Beta100.0%
Revenue-Price Divergence (1Y+)86.3%Revenue-Price Divergence (6M)67.1%200 SMA Touch47.7%Support Confirmation0.0%Support level
$0.201975
Industry
Other Pharmaceuticals
COSM Signal Track Record
How signals performed across all stocks →What COSM's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 43 | -11.3% | 37% | September 18, 2026 |
| Bollinger Band Breakdown | 25 | -3.3% | 44% | June 11, 2026 |
| Bollinger Band Breakout | 20 | -21.9% | 25% | September 18, 2026 |
| 200-Day Moving Average TouchActive now | 3 | -25.9% | 0% | September 21, 2026 |
| Any 20-session window (baseline) | -7.8% | 35% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About COSM
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus. The company provides prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names.…
- Sector
- Health Care
- Industry
- Other Pharmaceuticals
- Employees
- 163
- Website
- www.cosmosholdingsinc.com/
Fundamentals
- 1-day range
- $0.324$0.3401
- Market cap
- $13.72M
- P/E (trailing)
- —
- P/E (forward)
- 4.73
- EPS (trailing)
- $-0.62
- Dividend yield
- —
- Beta
- 4.50
- Avg. volume
- 3.43M
- Dividend pay date
- November 21, 2017
52-week range
$0.1616$1.26
How Cosmos Health Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Apr 15, 2026 · via SEC EDGAR / Finnhub
Gross Profit$7.90M(12%)
Operating Income-$16.70M(-26%)
Forecasts
1 analyst ratings
Buy 86%
Hold 14%
Sell 0%
1-year price forecast
High
$4.5
+1258.7%
Median
$4.5
+1258.7%
Low
$4.5
+1258.7%
Cosmos Health Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- COSMCosmos Health Inc. Common Stock$0.331▼ 1.49%Market cap $13.72MP/E —$0.1616$1.26
- HKPDCellyan Biotechnology Co. Ltd Class A Ordinary Shares$0.11▲ 0.00%Market cap $16.93MP/E —$0.095$1.72
- MEDSDataMeds AI Inc. Common Stock$2.63▼ 7.72%Market cap $7.52MP/E —$0.8225$12.31
- ZSTKZeroStack Corp. Common Stock$4▼ 5.21%Market cap $30.78MP/E —$1.32$20.45
- NUSNu Skin Enterprises Inc. Common Stock$5.14▼ 1.34%Market cap $251.98MP/E 4.30$4.45$11.67
- HLFHerbalife Ltd. Common Shares$14.6▲ 0.21%Market cap $1.19BP/E 9.24$7.56$20.4
- CAHCardinal Health Inc. Common Stock$254.06▲ 0.14%Market cap $55.66BP/E 33.97$152.46$258.3
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| COSM Cosmos Health Inc. Common Stock | $13.72M | — | $0.331 | ▼ 1.49% | $0.1616$1.26 |
| HKPD Cellyan Biotechnology Co. Ltd Class A Ordinary Shares | $16.93M | — | $0.11 | ▲ 0.00% | $0.095$1.72 |
| MEDS DataMeds AI Inc. Common Stock | $7.52M | — | $2.63 | ▼ 7.72% | $0.8225$12.31 |
| ZSTK ZeroStack Corp. Common Stock | $30.78M | — | $4 | ▼ 5.21% | $1.32$20.45 |
| NUS Nu Skin Enterprises Inc. Common Stock | $251.98M | 4.30 | $5.14 | ▼ 1.34% | $4.45$11.67 |
| HLF Herbalife Ltd. Common Shares | $1.19B | 9.24 | $14.6 | ▲ 0.21% | $7.56$20.4 |
| CAH Cardinal Health Inc. Common Stock | $55.66B | 33.97 | $254.06 | ▲ 0.14% | $152.46$258.3 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Cosmos Health Reaches 6,287 Active U.S. Subscriptions Generating ~$920K In Monthly Renewal Value; 60.5% Of Online Orders Include Subscriptions, Rising To More Than 75% In Recent Days As Adoption Acceleratesbenzinga · 10/14/2026
- Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 MillionYahoo · 10/7/2026
- COSM Continues to Surge Revenue GrowthYahoo · 10/7/2026
- Cosmos Health Sees Q3 Sales $17.400M vs $20.886M EstBenzinga · 10/7/2026
- Cosmos Health FY2026 Revenue expected to be more than $90.000M vs $84.300M EstBenzinga · 10/7/2026
- Cosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 BillionYahoo · 10/1/2026
- COSM Continues to Grow BusinessYahoo · 9/29/2026
- Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized RevenueYahoo · 9/29/2026
- Cosmos Health’s CosmoFarm Reports Q2 Revenue Of Over $15M, $60M Annualized Run Rate; Says Robotics, Automation And AI-Enabled Systems Across Procurement, Inventory And Order Execution, With Capacity That Could Support A Further $40M Or More In Annual Revenue, Which Would Provide Infrastructure For Annualized Revenue Above $100MBenzinga · 9/29/2026
Insider Activity
Insider Actions →Acquired
5.77M
Disposed
3.27M
- Siokas Grigorios · July 30, 2026 · Buy349.8K @ $0.2001
- Terzis Georgios · July 29, 2026 · Grant328.4K @ $0.1827
- Siokas Grigorios · July 29, 2026 · Buy766.3K @ $0.1827
- Terzis Georgios · June 16, 2026 · Buy168.1K @ $0.2498
- Siokas Grigorios · June 11, 2026 · Buy218.4K @ $0.206
- Siokas Grigorios · June 10, 2026 · Buy701.4K @ $0.2281
- Terzis Georgios · May 19, 2026 · Conversion850.0K
- Terzis Georgios · May 19, 2026 · Grant850.0K @ $0.283
- Siokas Grigorios · May 19, 2026 · Conversion2.35M
- Siokas Grigorios · May 19, 2026 · Grant2.35M @ $0.283
- Karkantzos Theodoros Christos · May 19, 2026 · Conversion35.0K
- Karkantzos Theodoros Christos · May 19, 2026 · Grant20.0K @ $0.283
- Hoidas John James · May 19, 2026 · Conversion20.0K
- Hoidas John James · May 19, 2026 · Grant20.0K @ $0.283
- Demetriades Demetrios G. · May 19, 2026 · Conversion20.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 1.67M
- Total value held
- $509.3K
- Institutional holders
- 21
Top holders this quarter
- Unknown390.5K
- Unknown336.6K
- Unknown318.1K
- Unknown267.8K
- Unknown140.0K
- Unknown67.3K
- Unknown45.2K
- Unknown40.5K
- Unknown20.6K
- Unknown17.7K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Cosmos Health Subsidiaries Report Record Revenue Milestones
Cosmos Health reported that its CosmoFarm division reached an annualized revenue run rate above $60 million, a 4.3x increase since acquisition. The company stated that robotics and AI systems are expanding capacity to support over $100 million in future revenue. Additionally, its contract manufacturing and Cana Laboratories divisions surpassed $20 million in implied revenue each.
Cosmos Health Subsidiaries Report Record Revenue Milestones. Cosmos Health reported that its CosmoFarm division reached an annualized revenue run rate above $60 million, a 4.3x increase since acquisition. The company stated that robotics and AI systems are expanding capacity to support over $100 million in future revenue. Additionally, its contract manufacturing and Cana Laboratories divisions surpassed $20 million in implied revenue each.